“Migraine Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.
The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Migraine Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years.
-
Migraine companies working in the treatment market are Axsome Therapeutics, Tonix Pharmaceuticals, Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment
-
Emerging Migraine therapies in the different phases of clinical trials are- TNX1900, LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.
-
In September 2024, Click Therapeutics, Inc., a pioneer in Digital Therapeutics™, announced achieving the primary endpoint in the pivotal randomized, double-blind, controlled, decentralized ReMMi-D study (NCT05853900) evaluating CT-132 for migraine prevention. After 12 weeks of treatment, CT-132 demonstrated a statistically significant reduction in monthly migraine days (MMDs) compared to sham treatment (-0.9 MMDs, p=0.005) in the ITT population of 568 participants, with the treatment group experiencing a reduction of -3.04 MMDs by the study's conclusion.
-
In September 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common conditions, announced the launch of a pivotal Phase 2 trial evaluating BHV-2100, a potential first-in-class orally administered TRPM3 antagonist, for the acute treatment of migraine.
-
In April 2024, Teva Pharmaceuticals has revealed promising results from a Phase III study assessing Ajovy (fremanezumab) for migraine prevention in Chinese adult patients. Teva's Ajovy is already approved for migraine prevention in adults in the US and Europe, having received regulatory approval from the US Food and Drug Administration in 2018 and the European Medicines Agency in 2019.
-
In March 2024, H. Lundbeck, a biopharmaceutical company, launched the PROCEED Phase IIb investigation to assess the effectiveness and safety of Lu AG09222, a promising therapy for preventing migraines. This study comes after the positive outcomes observed in the HOPE Phase IIa trial, which provided evidence of the efficacy of Lu AG09222 when administered intravenously for migraine prevention.
Migraine Overview
Migraine is a neurological disorder characterized by recurring headaches, often on one side of the head, accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound. Migraines can occur with or without an aura, which are sensory disturbances like visual changes or tingling sensations that precede the headache. They are triggered by various factors, including stress, hormonal changes, certain foods, or environmental stimuli. While the exact cause is not fully understood, migraines are linked to genetic and environmental factors. Treatment includes pain relief medications, preventive therapies, and lifestyle modifications to reduce frequency and severity.
Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/migraine-pipeline-insight
Emerging Migraine Drugs Under Different Phases of Clinical Development Include:
-
AXS-07: Axsome Therapeutics
-
TNX1900: Tonix Pharmaceuticals
-
LY3451838: Eli Lilly and Company
-
STS-101: Satsuma Pharmaceuticals
-
PUR-3100: Pulmatrix
-
UB-313: Vaxxinity, Inc.
-
TNX-1900: Tonix Pharmaceuticals, Inc
-
ABP-450: AEON Biopharma, Inc.
-
AXS 07: Axsome Therapeutics
-
Zavegepant: Pfizer
Migraine Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Migraine Molecule Type
Migraine Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Migraine Pipeline Therapeutics Assessment
-
Migraine Assessment by Product Type
-
Migraine By Stage and Product Type
-
Migraine Assessment by Route of Administration
-
Migraine By Stage and Route of Administration
-
Migraine Assessment by Molecule Type
-
Migraine by Stage and Molecule Type
DelveInsight's Migraine Report covers around 30+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies
Some of the key companies in the Migraine Therapeutics Market include:
Key companies developing therapies for Migraine are - GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.
Migraine Pipeline Analysis:
The Migraine pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
-
Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Migraine drugs and therapies
Migraine Pipeline Market Drivers
-
Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.
Migraine Pipeline Market Barriers
-
However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.
Scope of Migraine Pipeline Drug Insight
-
Coverage: Global
-
Key Migraine Companies: Axsome Therapeutics, Tonix Pharmaceuticals, Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others
-
Key Migraine Therapies: TNX1900, LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others
-
Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
-
Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials
Table of Contents
1. Migraine Report Introduction
2. Migraine Executive Summary
3. Migraine Overview
4. Migraine- Analytical Perspective In-depth Commercial Assessment
5. Migraine Pipeline Therapeutics
6. Migraine Late Stage Products (Phase II/III)
7. Migraine Mid Stage Products (Phase II)
8. Migraine Early Stage Products (Phase I)
9. Migraine Preclinical Stage Products
10. Migraine Therapeutics Assessment
11. Migraine Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Migraine Key Companies
14. Migraine Key Products
15. Migraine Unmet Needs
16 . Migraine Market Drivers and Barriers
17. Migraine Future Perspectives and Conclusion
18. Migraine Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
